- $352.54m
- $363.38m
Brief: Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
Brief: CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Cytodyn Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer
Brief: Cytodyn Announces Completion Of FDA Meeting On Phase 2 Study Of Leronlimab
Brief: CytoDyn Announces Settlement with Amarex Clinical Research
Brief: Cytodyn Announces Webcast To Provide Company Update
Brief: Cytodyn Appoints Jacob Lalezari M.D. As Interim CEO
Brief: Cytodyn Highlights Nih Grant For Hiv Functional Cure Preclinical Study Of Gene Therapy Based On Leronlimab
Brief: CytoDyn Announces Resolution Of Legal Dispute With Former Chief Medical Officer
Brief: CytoDyn Announces Partial Clinical Hold Of HIV Program And Full Clinical Hold Of Covid-19 Program
Brief: Cytodyn Receives Positive Response From FDA In Regard To Its Phase 3, Registrational Trial In Covid-19 Critically Ill Population
Brief: Cytodyn Submits Cmc (Manufacturing) Section Of Hiv BLA To FDA Under Previously Authorized Rolling Review Last (Clinical) Section Will Complete Full BLA Submission
Brief: Health Canada Authorizes Emergency Use Of Leronlimab For Treatment Of First Triple-Negative Breast Cancer Patient In Canada
Brief: Cytodyn Submits The First Of Three Main Sections Of HIV BLA To FDA Under Previously Authorized Rolling Review
Brief: Cytodyn Submits Breakthrough Therapy Designation Application To FDA For Leronlimab As A Treatment For Metastatic Triple-Negative Breast Cancer
Brief: Cytodyn Announces FDA Accepts Revised Rolling Review Timeline For Resubmission Of Its BLA
Brief: Cytodyn Announces Treatment Of First Patient In Pivotal Phase 3 Trial For Critically Ill COVID-19 Patients In Brazil
Delaware court rejects activist's attempt to control CytoDyn's board